Alnylam appoints Yvonne Greenstreet as CEO effective Jan 1, 2022; discloses compensation

ALNYLAM PHARMACEUTICALS, INC.

Yvonne Greenstreet, formerly President and COO, becomes CEO on Jan 1, 2022.
Annual base salary of $850,000; target bonus 100% of base salary for 2022 performance year.
Initial equity: $5M stock option granting on Dec 31, 2021; additional $2.5M option and $7.5M PSUs in Feb 2022.
$250,000 one-time relocation cash award with repayment obligation if termination for cause within 24 months.
Severance: pre-Change-in-Control no cash severance but continued vesting for 2 years; post-CIC double trigger with 2x salary+bonus and full acceleration.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Yvonne L. Greenstreet

Chief Executive Officer

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2022-01-01
Filed: December 20, 2021, 6:59 PM ET

Yvonne L. Greenstreet, MBChB, MBA, Alnylam Pharmaceuticals, Inc.’s (the “Company”) current President and Chief Operating Officer, has been appointed Chief Executive Officer of the Company effective January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Yvonne L. Greenstreet, MBChB, MBA, Alnylam Pharmaceuticals, Inc.’s (the “Company”) current President and Chief Operating Officer, has been appointed Chief Executive Officer of the Company effective January 1, 2022.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-362387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.